Revvity, Inc. (RVTY)
| Market Cap | 12.79B +24.3% |
| Revenue (ttm) | 2.91B +4.1% |
| Net Income | 237.55M -16.7% |
| EPS | 2.09 -11.5% |
| Shares Out | 111.56M |
| PE Ratio | 54.78 |
| Forward PE | 20.30 |
| Dividend | $0.28 (0.24%) |
| Ex-Dividend Date | Oct 23, 2026 |
| Volume | 1,050,532 |
| Open | 114.98 |
| Previous Close | 114.24 |
| Day's Range | 113.74 - 115.51 |
| 52-Week Range | 81.22 - 118.30 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 121.07 (+5.59%) |
| Earnings Date | Aug 4, 2026 |
About RVTY
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including... [Read more]
Financial Performance
In 2025, Revvity's revenue was $2.86 billion, an increase of 3.67% compared to the previous year's $2.76 billion. Earnings were $241.20 million, a decrease of -10.79%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for RVTY stock is "Buy." The 12-month stock price target is $121.07, which is an increase of 5.59% from the latest price.
News
Revvity price target raised to $126 from $125 at Evercore ISI
Evercore ISI raised the firm’s price target on Revvity (RVTY) to $126 from $125 and keeps an Outperform rating on the shares.
Revvity price target raised to $110 from $100 at Stifel
Stifel raised the firm’s price target on Revvity (RVTY) to $110 from $100 and keeps a Hold rating on the shares.
Revvity raises annual profit, revenue forecasts on strong diagnostics demand
Medical equipment maker Revvity raised its annual profit and revenue forecasts on Tuesday, after topping Wall Street estimates for the second quarter helped by improving demand for its drug-developm...
Revvity Earnings Call Transcript: Q2 2026
Q2 2026 saw 3% organic growth and adjusted EPS of $1.41, both above guidance, driven by strong Diagnostics and AI-related demand in Life Sciences. Full-year outlook was raised for organic growth, margins, and EPS, with robust cash flow and a pending China Immunodiagnostics divestiture.
Revvity Slides: Q2 2026
Revvity has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 4, 2026.
Revvity Earnings release: Q2 2026
Revvity released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Revvity reports Q2 adjusted EPS $1.41, consensus $1.22
Reports Q2 revenue $730M, consensus $703.18M. “Revvity (RVTY) delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base,...
Revvity enters definitive agreement to divest China Immunodiagnostics business
The company recently entered into a definitive agreement to divest its Immunodiagnostics business in China, which represented approximately 6% of the company’s total revenue in fiscal year 2025. The t...
Revvity raises FY26 adjusted EPS view to $5.30-$5.40 from $5.20-$5.30
FY26 consensus $5.25. Raises FY26 revenue view to $2.83B-$2.86B from $2.81B-$2.84B, consensus $2.83B.
Revvity Announces Financial Results for the Second Quarter of 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing op...
Revvity Board Declares Quarterly Dividend
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on Novem...
Revvity Announces Development of High-Throughput T-SPOT.TB Automated Platform for Clinical Labs
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages ...
Revvity Launches “Signals for Startups” to Help Emerging Biotechs Build Scalable Digital Foundations from Day One
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. announced that its Revvity Signals Software business is launching Signals for Startups, a new program designed to help emerging biotechnology companies a...
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today published its 2026 Impact Report, highlighting the Company's sustainability, social and governance strategy, initiatives and performan...
Revvity price target raised to $130 from $120 at TD Cowen
TD Cowen raised the firm’s price target on Revvity (RVTY) to $130 from $120 and keeps a Buy rating on the shares. The firm adjusted targets in the tools space…
Revvity to Hold Earnings Call on Tuesday, August 4, 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its second quarter 2026 financial results prior to market open on Tuesday, August 4, 2026. The Company...
Revvity price target raised to $125 from $110 at Evercore ISI
Evercore ISI analyst Vijay Kumar raised the firm’s price target on Revvity (RVTY) to $125 from $110 and keeps an Outperform rating on the shares. The firm’s Q2 preview for…
Revvity Signals Software business joined Anthropic’s directory
Revvity (RVTY) announced that its Revvity Signals Software business has joined Anthropic’s directory for Model Context Protocol connectors, enabling scientists to access Signals AI capabilities and co...
Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol (MCP) connectors, enabling ...
Revvity resumed with a Market Perform at Bernstein
Bernstein resumed coverage of Revvity (RVTY) with a Market Perform rating and $115 price target following a return from maternity leave. “Many things” are going right for the life science…
Revvity launches Signals AI framework
Revvity (RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One pla...
Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabili...
Revvity Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Diagnostics and life sciences segments delivered strong growth, with reproductive health and immunodiagnostics outperforming expectations. Strategic divestiture of China immunodiagnostics will support share buybacks and targeted acquisitions. Major software launches and AI integration, along with margin expansion and robust execution, position the company for continued growth.
Revvity assumed with a Peer Perform at Wolfe Research
Wolfe Research assumed coverage of Revvity (RVTY) with a Peer Perform rating. The firm notes that while it is “intrigued” by the stock’s general valuation and likes the recent portfolio…
Revvity Transcript: Bank of America Global Healthcare Conference 2026
Strong quarterly results were highlighted by the strategic divestiture of the China immunodiagnostics business, improving growth and margins. Life sciences and software segments showed positive momentum, with new AI-driven products and major software launches expected to drive future growth.